HBK Investments’s Akebia Therapeutics AKBA Stock Holding History

HBK Investments’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-115,000	Closed	-$1.1M	–	999
2018 Q1	$1.1M	Buy	+115,000	New	+$1.61M	0.01%	600

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HBK Investments's AKBA Position: Q2 2018 in Review

HBK Investments sold out of Akebia Therapeutics (AKBA) in Q2 2018, closing a stake of 115,000 shares — an estimated $1.1M sold.

HBK Investments first reported a position in AKBA in Q1 2018 and held it in 1 quarter. The position peaked at $1.1M in Q1 2018. 145 funds tracked by Wall St. Rank hold AKBA as of Q2 2018.

HBK Investments reported no remaining Akebia Therapeutics position as of Q2 2018 after selling out during the quarter.
HBK Investments sold 115,000 Akebia Therapeutics shares in Q2 2018, an estimated $1.1M.
HBK Investments first reported a position in Akebia Therapeutics in Q1 2018 and held it in 1 quarter.
HBK Investments's Akebia Therapeutics position peaked at $1.1M in Q1 2018.
145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2018.

Based on HBK Investments's 13F filing for Q2 2018, filed 14 Aug 2018.